Related Experiment Videos
Low-Dose Aspirin Prophylaxis for Preeclampsia and the Risk of Postpartum Hypertensive Outcomes: A Propensity Score
Ema Mujic1, Sojourna Ferguson2, Nyia L Noel2
1Boston University School of Public Health, Department of Epidemiology, Massachusetts, United States, Boston.
Objective:
The U.S. Preventive Services Task Force (USPSTF) recommends low-dose aspirin (LDA, 81 mg/day) after 12 weeks of pregnancy to reduce preeclampsia risk. While its effectiveness for prevention is well-established, less is known about the effects on postpartum hypertensive outcomes. This study aimed to examine whether LDA prescription in pregnancy (≤36 weeks' gestation) is associated with postpartum hypertensive outcomes through 6 weeks postpartum.
Study Design:
This retrospective cohort study used electronic medical record data from deliveries (2018-2019) at New England's largest safety-net hospital. Among 1,773 patients meeting USPSTF criteria for LDA initiation, 523 were prescribed LDA. Patients were propensity score (PS)-matched 1:1 on risk factors and prenatal care site (primary matched cohort: n = 784); a secondary PS-matched analysis was restricted to patients with one or more high-level risk factors (high-risk matched cohort: n = 212). Primary outcomes included antihypertensive use during hospitalization, antihypertensive prescription at discharge, and severe-range postpartum hypertension. Risk ratios (RRs) were estimated using log-binomial regression. Joint effects of LDA and preeclampsia were assessed using LDA -/PreE- as reference.
Results:
In the primary matched cohort, compared with LDA- patients, LDA+ patients had higher rates of antihypertensive use during hospitalization (RR: 1.54, 95% confidence interval [CI]: 1.12-2.12), discharge prescription (RR: 1.42, 95% CI: 0.95-2.12), and severe-range hypertension (RR: 1.48, 95% CI: 1.06-2.06). Associations did not persist in the high-risk matched cohort. In joint effects analyses, preeclampsia was associated with postpartum hypertensive outcomes regardless of LDA. Compared with LDA -/PreE - , the LDA +/PreE+ group had elevated risks; point estimates were highest among LDA -/PreE+ patients.
Conclusion:
Associations between LDA and postpartum hypertensive outcomes may vary by baseline risk. Among high-risk patients, LDA was not associated with increased postpartum risk and may attenuate severity for those developing preeclampsia. Further study is needed to clarify LDA's role in reducing postpartum cardiovascular risk.
Key Points:
· LDA showed no overall reduction in postpartum hypertensive outcomes.. · In high-risk patients, LDA may lessen postpartum hypertensive complications.. · Among patients with preeclampsia, LDA use was linked to lower postpartum risks.. · Results highlight the need to study LDA in postpartum cardiovascular health..
Related Concept Videos
01:20Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
01:23Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast, controlled...
01:23Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
01:31Adrenergic Antagonists: ɑ and β-Receptor Blockers
01:20Drugs for Peptic Ulcer Disease: Prostaglandin Analogs as Mucosal Protective Agents
Non-steroidal anti-inflammatory drugs (NSAIDs) can induce peptic ulcers by inhibiting cyclooxygenase, decreasing...
01:30Anticoagulant Drugs: Low-Molecular-Weight Heparins